@stockplaymaker1 Check out #IXHL huge catalysts for December Phase 2 FDAupdates released any day. Dec 18th investors meeting and updates on phase 2/3 starting. The big run up in July/August will be dwarfed with this next run. This is the sleeping Dollar Giant.

The FDA’s new Plausible Mechanism Pathway represents a major shift in how individualized, N=1 therapies are evaluated. A thoughtful framework designed for diseases where traditional trials are impossible and where biology offers a clear path forward. Read our full breakdown on what PMP means for the future of rare disease treatment and precision medicine. oncodaily.com/industry/fdas-… @US_FDA @FDA @MartyMakary #PlausibleMechanismPathway #FDAUpdates #RegulatoryScience #PrecisionMedicine #IndividualizedTherapies #FDA

The #FDA approved tafasitamab-cxix with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma. Read more #FDAupdates: ow.ly/ssWo50X1JY9

The #FDA approved tafasitamab-cxix with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma. Read more #FDAupdates: ow.ly/yrcM50WZ0IU

The FDA granted accelerated approval to sunvozertinib for adult patients with locally advanced or metastatic non-small cell lung cancer. Read more #FDAupdates here: ow.ly/5RLO50WZ0wm #NSCLC

The FDA granted accelerated approval to sunvozertinib for adult patients with locally advanced or metastatic non-small cell lung cancer. Read more #FDAupdates here: ow.ly/bpux50WW4GT #NSCLC

The #FDA approved tafasitamab-cxix with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma. Read more #FDAupdates: ow.ly/nC7B50WUHTo

The FDA granted accelerated approval to sunvozertinib for adult patients with locally advanced or metastatic non-small cell lung cancer. Read more #FDAupdates here: ow.ly/YumO50WU47K #NSCLC

The FDA granted accelerated approval to sunvozertinib for adult patients with locally advanced or metastatic non-small cell lung cancer. Read more #FDAupdates here: ow.ly/8zIE50WOkZO #NSCLC

Staying on top of your health means staying informed. From new diabetes prevention research to FDA recalls and inspiring patient voices, here’s what you need to know this month. #HealthNews #PatientAdvocacy #FDAUpdates #ClinicalResearch #Fibromyalgia #PCOS Learn more: hubs.li/Q03Gf9zq0

The #FDA approved pembrolizumab for adults with resectable, locally advanced head and neck squamous cell carcinoma. Read more #FDAupdates here: ow.ly/ZNHq50WyRMs #HNSCC

The #FDA approved pembrolizumab for adults with resectable, locally advanced head and neck squamous cell carcinoma. Read more #FDAupdates here: ow.ly/ZNHq50WyRMs #HNSCC

The #FDA approved pembrolizumab for adults with resectable, locally advanced head and neck squamous cell carcinoma. Read more #FDAupdates here: ow.ly/N5jx50WyRMu #HNSCC

The #FDA approved pembrolizumab for adults with resectable, locally advanced head and neck squamous cell carcinoma. Read more #FDAupdates here: ow.ly/ZNHq50WyRMs #HNSCC

Looking to catch up on the latest #FDAupdates in cancer treatment? Read them here: ow.ly/Tplf50WrXx3 #CancerResearch

The FDA approved brentuximab vedotin in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma. ow.ly/wX2m50VvX9Q #LBCL #FDAupdates

The FDA granted traditional approval to acalabrutinib with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma. Read more: ow.ly/yNTu50VvXhl #MCL #FDAupdates

The FDA approved brentuximab vedotin in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma. ow.ly/7ftH50VvX9P #LBCL #FDAupdates

The FDA approved vimseltinib, a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor. ow.ly/Mk0450VvRTO #TGCT #FDAupdates

The FDA granted traditional approval to acalabrutinib with bendamustine and rituximab for adults with previously untreated #MantleCellLymphoma. Read more #FDAupdates here: ow.ly/qBsu50VeXox #MCL